|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nikolaou M, Pavlopoulou A, Georgakilas AG
and Kyrodimos E: The challenge of drug resistance in cancer
treatment: a current overview. Clin Exp Metastasis. 35:309–318.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang P, Yang HL, Yang YJ, Wang L and Lee
SC: Overcome cancer cell drug resistance using natural products.
Evid Based Complement Alternat Med. 2015:7671362015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alves IA, Miranda HM, Soares LA and Randau
KP: Simaroubaceae family: Botany, chemical composition and
biological activities. Rev Bras Farmacogn. 24:481–501. 2014.
View Article : Google Scholar
|
|
5
|
Ding H, Yu X, Hang C, Gao K, Lao X, Jia Y
and Yan Z: Ailanthone: A novel potential drug for treating human
cancer. Oncol Lett. 20:1489–1503. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Casinovi CG, Ceccherelli P, Grandolini G
and Bellavita V: On the structure of Ailanthone. Tetrahedron Lett.
5:3991–3997. 1964. View Article : Google Scholar
|
|
7
|
Ishibashi M, Tsuyuki T, Murae T, Hirota H,
Takahashi T, Itai A and Iitaka Y: Constituents of the root bark of
Ailanthus altissima swingle. Isolation and X-ray crystal structures
of shinjudilactone and shinjulactone C and conversion of ailanthone
into shinjudilactone. Bull Chem Sok Jpn. 56:3683–3693. 1983.
View Article : Google Scholar
|
|
8
|
Hou S, Cheng Z, Wang W, Wang X and Wu Y:
Ailanthone exerts an antitumor function on the development of human
lung cancer by upregulating microRNA-195. J Cell Biochem.
120:10444–10451. 2019. View Article : Google Scholar
|
|
9
|
Liu W, Liu X, Pan Z, Wang D, Li M, Chen X,
Zhou L, Xu M, Li D and Zheng Q: Ailanthone induces cell cycle
arrest and apoptosis in melanoma B16 and A375 cells. Biomolecules.
9:2752019. View Article : Google Scholar :
|
|
10
|
Daga M, Pizzimenti S, Dianzani C, Cucci
MA, Cavalli R, Grattarola M, Ferrara B, Scariot V, Trotta F and
Barrera G: Ailanthone inhibits cell growth and migration of
cisplatin resistant bladder cancer cells through down-regulation of
Nrf2, YAP, and c-Myc expression. Phytomedicine. 56:156–164. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen Y, Zhu L, Yang X, Wei C, Chen C, He Y
and Ji Z: Ailanthone induces G2/M cell cycle arrest and apoptosis
of SGC-7901 human gastric cancer cells. Mol Med Rep. 16:6821–6827.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
He Y, Peng S, Wang J, Chen H, Cong X, Chen
A, Hu M, Qin M, Wu H, Gao S, et al: Ailanthone targets p23 to
overcome MDV3100 resistance in castration-resistant prostate
cancer. Nat Commun. 7:131222016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhuo Z, Hu J, Yang X, Chen M, Lei X, Deng
L, Yao N, Peng Q, Chen Z, Ye W and Zhang D: Ailanthone inhibits
Huh7 cancer cell growth via cell cycle arrest and apoptosis in
vitro and in vivo. Sci Rep. 5:161852015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
15
|
Danial NN and Korsmeyer SJ: Cell death:
Critical control points. Cell. 116:205–219. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu RY, Zeng Y, Lei Z, Wang L, Yang H, Liu
Z, Zhao J and Zhang HT: JAK/STAT3 signaling is required for
TGF-β-induced epithelial-mesenchymal transition in lung cancer
cells. Int J Oncol. 44:1643–1651. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang W, Yu LF, Zhong J, Wu W, Zhu JY,
Jiang FX and Wu YL: Stat3 is involved in angiotensin II-induced
expression of MMP2 in gastric cancer cells. Dig Dis Sci.
54:2056–2062. 2009. View Article : Google Scholar
|
|
18
|
Xiong H, Zhang ZG, Tian XQ, Sun DF, Liang
QC, Zhang YJ, Lu R, Chen YX and Fang JY: Inhibition of JAK1,
2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces
tumor cell invasion in colorectal cancer cells. Neoplasia.
10:287–297. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Qi F, Zhao L, Zhou A, Zhang B, Li A, Wang
Z and Han J: The advantages of using traditional Chinese medicine
as an adjunctive therapy in the whole course of cancer treatment
instead of only terminal stage of cancer. Biosci Trends. 9:16–34.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bezwoda WR, MacDonald DF, Gear JS, Derman
DP, Bothwell TH, Sqi S, Hurwitz S and Lewis D: Combination
chemotherapy including bleomycin in the treatment of advanced
Hodgkin's disease. S Afr Med J. 53:369–373. 1978.PubMed/NCBI
|
|
21
|
Durant JR, Gams RA, Bartolucci AA and
Dorfman RF: BCNU with and without cyclophosphamide, vincristine,
and prednisone (COP) and cycle-active therapy in non-Hodgkin's
lymphoma. Cancer Treat Rep. 61:1085–1096. 1977.PubMed/NCBI
|
|
22
|
Wong MY and Chiu GN: Liposome formulation
of co-encapsulated vincristine and quercetin enhanced antitumor
activity in a trastuzumab-insensitive breast tumor xenograft model.
Nanomedicine. 7:834–840. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Munker S, Vogelhuber M, Bornschein J,
Stroszczynski C, Evert M, Schlitt H, Herr W and Teufel A: EpiCO
(epirubicin, cyclophosphamide and vincristine) as treatment for
extrapulmonary high-grade neuroendocrine neoplasms. Z
Gastroenterol. 58:133–136. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Büyükkapu Bay S, Kebudi R, Görgün O,
Zülfikar B, Darendeliler E and Çakır FB: Vincristine, irinotecan,
and temozolomide treatment for refractory/relapsed pediatric solid
tumors: A single center experience. J Oncol Pharm Pract.
25:1343–1348. 2019. View Article : Google Scholar
|
|
25
|
Weaver BA: How Taxol/paclitaxel kills
cancer cells. Mol Biol Cell. 25:2677–2681. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Caparica R, Bruzzone M, Poggio F, Ceppi M,
de Azambuja E and Lambertini M: Anthracycline and taxane-based
chemotherapy versus docetaxel and cyclophosphamide in the adjuvant
treatment of HER2-negative breast cancer patients: A systematic
review and meta-analysis of randomized controlled trials. Breast
Cancer Res Treat. 174:27–37. 2019. View Article : Google Scholar
|
|
27
|
Reck M, Brahmer J, Bennett B, Taylor F,
Penrod JR, DeRosa M, Dastani H, Spigel DR and Gralla RJ: Evaluation
of health-related quality of life and symptoms in patients with
advanced non-squamous non-small cell lung cancer treated with
nivolumab or docetaxel in CheckMate 057. Eur J Cancer. 102:23–30.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
da Rocha AB, Lopes RM and Schwartsmann G:
Natural products in anticancer therapy. Curr Opin Pharmacol.
1:364–369. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang Y, Zhang C and Min D: Ailanthone
up-regulates miR-449a to restrain acute myeloid leukemia cells
growth, migration and invasion. Exp Mol Pathol. 108:114–120. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ni Z, Yao C, Zhu X, Gong C, Xu Z, Wang L,
Li S, Zou C and Zhu S: Ailanthone inhibits non-small cell lung
cancer cell growth through repressing DNA replication via
downregulating RPA1. Br J Cancer. 117:1621–1630. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fuchs Y and Steller H: Programmed cell
death in animal development and disease. Cell. 147:742–758. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kang MH and Reynolds CP: Bcl-2 inhibitors:
Targeting mitochondrial apoptotic pathways in cancer therapy. Clin
Cancer Res. 15:1126–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Philchenkov A, Zavelevich M, Kroczak TJ
and Los M: Caspases and cancer: Mechanisms of inactivation and new
treatment modalities. Exp Oncol. 26:82–97. 2004.PubMed/NCBI
|
|
36
|
Rohn JL and Noteborn MH: The viral death
effector apoptin reveals tumor-specific processes. Apoptosis.
9:315–322. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Terrano DT, Upreti M and Chambers TC:
Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation
acts as a functional link coupling mitotic arrest and apoptosis.
Mol Cell Biol. 30:640–656. 2010. View Article : Google Scholar :
|
|
38
|
Siveen KS, Sikka S, Surana R, Dai X, Zhang
J, Kumar AP, Tan BK, Sethi G and Bishayee A: Targeting the STAT3
signaling pathway in cancer: Role of synthetic and natural
inhibitors. Biochim Biophys Acta. 1845:136–154. 2014.PubMed/NCBI
|
|
39
|
Lee H, Jeong AJ and Ye SK: Highlighted
STAT3 as a potential drug target for cancer therapy. BMB Rep.
52:415–423. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zeng J, Tang ZH, Liu S and Guo SS:
Clinicopathological significance of overexpression of interleukin-6
in colorectal cancer. World J Gastroenterol. 23:1780–1786. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Waldner MJ and Neurath MF: Master
regulator of intestinal disease: IL-6 in chronic inflammation and
cancer development. Semin Immunol. 26:75–79. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Velikova TV, Miteva L, Stanilov N,
Spassova Z and Stanilova SA: Interleukin-6 compared to the other
Th17/Treg related cytokines in inflammatory bowel disease and
colorectal cancer. World J Gastroenterol. 26:1912–1925. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lee KS, Kwak Y, Nam KH, Kim DW, Kang SB,
Choe G, Kim WH and Lee HS: c-MYC copy-number gain is an independent
prognostic factor in patients with colorectal cancer. PLoS One.
10:e01397272015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Leslie K, Lang C, Devgan G, Azare J,
Berishaj M, Gerald W, Kim YB, Paz K, Darnell JE, Albanese C, et al:
Cyclin D1 is transcriptionally regulated by and required for
transformation by activated signal transducer and activator of
transcription 3. Cancer Res. 66:2544–2552. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lee DH, Sung KS, Bartlett DL, Kwon YT and
Lee YJ: HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis
by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in
colorectal cancer cells. Cell Signal. 27:293–305. 2015. View Article : Google Scholar
|
|
46
|
Tian Y, Ye Y, Gao W, Chen H, Song T, Wang
D, Mao X and Ren C: Aspirin promotes apoptosis in a murine model of
colorectal cancer by mechanisms involving downregulation of
IL-6-STAT3 signaling pathway. Int J Colorectal Dis. 26:13–22. 2011.
View Article : Google Scholar
|
|
47
|
Liu H, Ren G, Wang T, Chen Y, Gong C, Bai
Y, Wang B, Qi H, Shen J, Zhu L, et al: Aberrantly expressed Fra-1
by IL-6/STAT3 transactivation promotes colorectal cancer
aggressiveness through epithelial-mesenchymal transition.
Carcinogenesis. 36:459–468. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Han C, Sun B, Zhao X, Zhang Y, Gu Q, Liu
F, Zhao N and Wu L: Phosphorylation of STAT3 promotes vasculogenic
mimicry by inducing epithelial-to-mesenchymal transition in
colorectal cancer. Technol Cancer Res Treat. 16:1209–1219. 2017.
View Article : Google Scholar
|
|
49
|
Angevin E, Tabernero J, Elez E, Cohen SJ,
Bahleda R, van Laethem JL, Ottensmeier C, Lopez-Martin JA, Clive S,
Joly F, et al: A phase I/II, multiple-dose, dose-escalation study
of siltuximab, an anti-interleukin-6 monoclonal antibody, in
patients with advanced solid tumors. Clin Cancer Res. 20:2192–2204.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Fogelman D, Cubillo A, García-Alfonso P,
Mirón MLL, Nemunaitis J, Flora D, Borg C, Mineur L, Vieitez JM,
Cohn A, et al: Randomized, double-blind, phase two study of
ruxolitinib plus regorafenib in patients with relapsed/refractory
metastatic colorectal cancer. Cancer Med. 7:5382–5393. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Beatty GL, Shahda S, Beck T, Uppal N,
Cohen SJ, Donehower R, Gabayan AE, Assad A, Switzky J, Zhen H and
Von Hoff DD: A phase Ib/II study of the JAK1 inhibitor, itacitinib,
plus nab-paclitaxel and gemcitabine in advanced solid tumors.
Oncologist. 24:14–e10. 2019. View Article : Google Scholar
|
|
52
|
Oh DY, Lee SH, Han SW, Kim MJ, Kim TM, Kim
TY, Heo DS, Yuasa M, Yanagihara Y and Bang YJ: Phase I study of
OPB-31121, an oral STAT3 inhibitor, in patients with advanced solid
tumors. Cancer Res Treat. 47:607–615. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Okamoto T, Inozume T, Mitsui H, Kanzaki M,
Harada K, Shibagaki N and Shimada S: Overexpression of GRIM-19 in
cancer cells suppresses STAT3-mediated signal transduction and
cancer growth. Mol Cancer Ther. 9:2333–2343. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Hong D, Kurzrock R, Kim Y, Woessner R,
Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, et al:
AZD9150, a next-generation antisense oligonucleotide inhibitor of
STAT3 with early evidence of clinical activity in lymphoma and lung
cancer. Sci Transl Med. 7:314ra1852015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Bharadwaj U, Kasembeli MM, Robinson P and
Tweardy DJ: Targeting janus kinases and signal transducer and
activator of transcription 3 to treat inflammation, fibrosis, and
cancer: Rationale, progress and caution. Pharmacol Rev. 72:486–526.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Song L, Wang Y, Zhen Y, Li D, He X, Yang
H, Zhang H and Liu Q: Piperine inhibits colorectal cancer migration
and invasion by regulating STAT3/Snail-mediated
epithelial-mesenchymal transition. Biotechnol Lett. 42:2049–2058.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zhou H, Chen S, Yang Y, Yang C, Chen D,
Yao Z and Sun B: Matrine enhances the efficacy of adriamycin
chemotherapy in osteosarcoma cells by the STAT3 pathway. Anticancer
Drugs. 30:1006–1012. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Cummins CB, Wang X, Nunez Lopez O, Graham
G, Tie HY, Zhou J and Radhakrishnan RS: Luteolin-mediated
inhibition of hepatic stellate cell activation via suppression of
the STAT3 pathway. Int J Mol Sci. 19:15672018. View Article : Google Scholar :
|
|
59
|
Hayakawa T, Yaguchi T and Kawakami Y:
Enhanced anti-tumor effects of the PD-1 blockade combined with a
highly absorptive form of curcumin targeting STAT3. Cancer Sci.
111:4326–4335. 2020. View Article : Google Scholar : PubMed/NCBI
|
